Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick T Gunning

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
ACS Medicinal Chemistry Letters|November 25, 2014
Nanomolar-Potency Small Molecule Inhibitor of STAT5 ProteinAbbarna A Cumaraswamy, Andrew M Lewis, Mulu Geletu, et al.
Journal of Medicinal Chemistry|August 24, 2013
Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myelomaBrent D G Page, Danielle C Croucher, Zhi Hua Li, et al.
ACS Medicinal Chemistry Letters|January 16, 2020
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid LeukemiaAndrew E Shouksmith, Justyna M Gawel, Nabanita Nawar, et al.
Journal of Medicinal Chemistry|July 17, 2020
Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 TargetingMuhammad Murtaza Hassan, Johan Israelian, Nabanita Nawar, et al.
Cancer Discovery|February 14, 2016
STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor PromotionDagmar Gotthardt, Eva M Putz, Eva Grundschober, et al.
European Journal of Medicinal Chemistry|July 3, 2020
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemiaJustyna M Gawel, Andrew E Shouksmith, Yasir S Raouf, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Journal of Medicinal Chemistry|August 27, 2025
Improved Pharmacokinetic Profiles of HDAC6 Inhibitors via Cap Group ModificationsOlasunkanmi O Olaoye, Fettah Erdogan, Maria Gracia-Hernandez, et al.
Plos One|April 3, 2014
Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsG Wei Xu, Julia I Toth, Sara R da Silva, et al.
Pharmaceuticals (Basel, Switzerland)|November 10, 2022
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell LymphomaHarsimran Kaur Garcha, Nabanita Nawar, Helena Sorger, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
ACS Medicinal Chemistry Letters|November 25, 2014
Nanomolar-Potency Small Molecule Inhibitor of STAT5 ProteinAbbarna A Cumaraswamy, Andrew M Lewis, Mulu Geletu, et al.
Journal of Medicinal Chemistry|August 24, 2013
Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myelomaBrent D G Page, Danielle C Croucher, Zhi Hua Li, et al.
ACS Medicinal Chemistry Letters|January 16, 2020
Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid LeukemiaAndrew E Shouksmith, Justyna M Gawel, Nabanita Nawar, et al.
Journal of Medicinal Chemistry|July 17, 2020
Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 TargetingMuhammad Murtaza Hassan, Johan Israelian, Nabanita Nawar, et al.
Cancer Discovery|February 14, 2016
STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor PromotionDagmar Gotthardt, Eva M Putz, Eva Grundschober, et al.
European Journal of Medicinal Chemistry|July 3, 2020
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemiaJustyna M Gawel, Andrew E Shouksmith, Yasir S Raouf, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Journal of Medicinal Chemistry|August 27, 2025
Improved Pharmacokinetic Profiles of HDAC6 Inhibitors via Cap Group ModificationsOlasunkanmi O Olaoye, Fettah Erdogan, Maria Gracia-Hernandez, et al.
Plos One|April 3, 2014
Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsG Wei Xu, Julia I Toth, Sara R da Silva, et al.
Pharmaceuticals (Basel, Switzerland)|November 10, 2022
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell LymphomaHarsimran Kaur Garcha, Nabanita Nawar, Helena Sorger, et al.
Pageof 10